stella
beta
Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) — Stella
Recruiting
Share this trial
Back to Low-risk Myelodysplastic Syndromes trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Trial locations
(3 sites)
France
CHU de Nice - Hôpital l'Archet - Service d'hématologie clinique, Nice
Hôpital Saint Louis - Service Hématologie séniors, Paris
Institut Gustave Roussy - Service d'hématologie, Villejuif
View full record on ClinicalTrials.gov